heart disease

[키워드] 1:1 20-hydroxyecdysone absence accumulation ACE2 Activation acute respiratory distress acute respiratory distress syndrome adaptive addition administration Airway Pressure all-cause mortality ALT Alter amenorrhea Analysis angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 Angiotensin converting enzyme-2 Anti-inflammatory anticipated approved ARDS arterial oxygen saturation AST Asymptomatic balance baseline being Belgium beneficiary Bilirubin BIO101 Biomarker Biomarkers birth control blinded Brazil breath Cardiomyopathy Care Caregivers caused clinical development Clinical finding Clinical findings clinical picture co-morbidities co-morbidity collected Compliance condition condom conducted confirmation Consumption Continuous Continuous Positive Airway Pressure Contraception contraceptive method coronavirus disease COVID-19 COVID-19 infection COVID-19 infection symptom COVID-19 infection symptoms COVID-19 patient COVID-19 patients criteria criterion daily dose Day death defined Department Deterioration develop diabetes diagnosis of COVID-19 dialysis discharge discharged disease dissemination DMC dose double-blind downstream ECMO Effect effective Efficacy Efficacy and safety EGFR element eligible participant Eligible participants endotracheal tube Endpoint enzyme etonogestrel EudraCT European evaluate event Evidence evidence of exclusion criteria expected exploratory extracorporeal membrane oxygenation female female participants Final FiO2 Flow following form France French functional Gault Gender healthcare healthcare facility heart disease High-flow oxygen higher risk hospital hospital care Hospitalization Hospitalized hypersensitivity hypertension IBM ICF Imbalance include Inclusion independent indication Infection Inflammation informed consent form injection Interim analyses interim analysis Intervention intrauterine device Intubated Invasive mechanical ventilation IWRS system lactating limit Liver function liver function tests male participants marker Mas receptor maximum measure mechanical ventilation medical intervention medication medications minute moderate morbidities Moribund Mortality mouth Multiorgan dysfunction muscles myocarditis negative urine pregnancy test Non-COVID-19 number obesity objective observation offer Older oral contraceptive outcome outlined oxygen Part participant partner pathway Pathways patients with COVID-19 patients with SARS-CoV-2 PCR performed Pericarditis Physical examination Placebo placebo-controlled Pneumonia positive airway pressure post-intervention post-menopausal powder pregnancy test pressure primary endpoint proof proportion Proportion of participant protocol public health randomised randomised controlled trial randomization RAS reached receive receiving receptor recruited recruitment Registered renal renal disease renal insufficiency Renin renin angiotensin system renin-angiotensin system reproduction required resource respiratory Respiratory distress syndrome Respiratory failure Respiratory function respiratory symptoms restored risk Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV2 SARS-CoV2 spike protein second secondary secondary endpoint security severe pneumonia Shock Social Security specimen Sperm Spike protein SpO2 Statistical power status Sterilization Stratification stratified study medication Study protocol supplementary material survival suspicion Symptom syndrome tachypnea target population tested Testing the primary endpoint therapeutic therapeutic option tissue Tolerability Total total bilirubin Treatment treatment arm treatment period Triage Trial Trial registration ULN Urine USA variety vasectomy Version Viral load water website
[DOI] 10.1186/s13063-020-04998-5 PMC 바로가기 [Article Type] Letter